Ademetionine improves QOL in affective disorders

Ademetionine may improve quality of life (QOL) in adult and elderly patients with mild mood disorders, reports Dr Paolo Pancheri from Italy.

In an open-label multicentre study, 198 outpatients in Switzerland aged 55–80 years with nonspecific mood deterioration received oral ademetionine 100mg twice daily for 2 months. QOL was measured using the specifically designed Behavioural and Quality Of Life (BQOL) self-assessment questionnaire at baseline and after 1 and 2 months of treatment. Results revealed that ademetionine was associated with statistically and clinically significant mean improvements from baseline in BQOL scores after 1 month, with further improvements observed after 2 months (33 and 49% increase in BQOL scores). All three BQOL components (physical, mental and social) indicated significant improvements over baseline. Improvements were significantly more pronounced for male, compared with female, patients. In addition, 87% of patients reported induced or improved wellbeing after ademetionine treatment.